MDWD

BEARISH

$17.65 Live

MediWound Ltd. · NASDAQ

Target $31.33 (+77.5%)

$14.9 52W Range $22.5

MDWD MediWound Ltd. - Fundamental Analysis

BEARISH

Console Chart News

MDWD Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$17.65

Analyst Target

$31.33

+77.5% Upside

52W High

$22.5

52W Low

$14.9

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026

Market cap

$226.84M

P/E

N/A

ROE

-63.9%

Profit margin

-140.8%

Debt/Equity

0.2

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

95%

MDWD exhibits severe financial distress as evidenced by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. The company is experiencing a catastrophic operational collapse with revenue plummeting by 68% YoY and operating margins sitting at -417.78%. While the balance sheet remains liquid with a Current Ratio of 2.33 and low debt, these are lagging indicators that cannot offset the rapid erosion of the top and bottom lines. There is a dangerous divergence between the fundamental decay and the 'Strong Buy' analyst consensus, suggesting the stock is priced on speculative hopes rather than data-driven value.

Key Strengths

Low Debt/Equity ratio of 0.20

Strong liquidity with a Current Ratio of 2.33

Healthy Quick Ratio of 2.16

Positive 1-year price performance (+6.4%)

Strong analyst target price ($31.33) relative to current price

Key Risks

Severe revenue contraction (-68% YoY and Q/Q)

Extreme operational inefficiency (Operating Margin -417.78%)

Critical Piotroski F-Score (1/9) signaling fundamental weakness

Excessive valuation multiples (P/S of 13.38) despite crashing growth

Negative ROE (-63.86%) and ROA (-19.77%)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Revenue collapse, Negative margins, Fundamental health failure (F-Score)

Confidence

90%

Value

10/100

No Graham Number available due to lack of positive earnings.

Positives

No standout positives identified.

Watchpoints

P/S ratio of 13.38 is unsustainable for a shrinking company
P/B of 5.19 is high for the sector given the losses

Future

5/100

Growth metrics are in a state of freefall.

Positives

No standout positives identified.

Watchpoints

Revenue growth is -68%
EPS growth is -55.6% YoY

Past

20/100

Long-term trend is heavily negative.

Positives

Short-term 1Y price recovery

Watchpoints

5-year price change of -51.4%
Inconsistent earnings track record

Health

25/100

Liquidity is the only saving grace, but operational health is failing.

Positives

Low leverage (Debt/Equity 0.20)
Strong current liquidity

Watchpoints

Piotroski F-Score of 1/9

Dividend

0/100

Non-dividend paying growth/biotech stock.

Positives

No standout positives identified.

Watchpoints

No dividend payments
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$17.65

Analyst Target

$31.33

Upside/Downside

+77.5%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MDWD and closest competitors.

Updated 2026-04-13

Company	5Y	3Y	1Y	6M	1M	1W
MDWD MediWound Ltd. Primary	-51.4%	+35.6%	+6.4%	-3.1%	+6.5%	+6.8%
MGNX MacroGenics, Inc. Peer	-88.9%	-46.5%	+173.2%	+111.6%	+15.7%	+9.1%
CVRX CVRx, Inc. Peer	-70.1%	-7.4%	-27.5%	-4.1%	+6.5%	-11.5%
LUCD Lucid Diagnostics Inc. Peer	-89.1%	-5.9%	+7.6%	+8.5%	-6.6%	+13.3%
CAMP CAMP4 THERAPEUTICS CORPORATION Peer	-56.6%	-56.6%	+78.8%	+41.3%	-25.9%	+5.4%

MDW

MediWound Ltd.

Primary

-51.4%

+35.6%

+6.4%

-3.1%

+6.5%

+6.8%

MGN

MacroGenics, Inc.

Peer

-88.9%

-46.5%

+173.2%

+111.6%

+15.7%

+9.1%

CVR

CVRx, Inc.

Peer

-70.1%

-7.4%

-27.5%

-4.1%

+6.5%

-11.5%

LUC

Lucid Diagnostics Inc.

Peer

-89.1%

-5.9%

+7.6%

+8.5%

-6.6%

+13.3%

CAM

CAMP4 THERAPEUTICS CORPORATION

Peer

-56.6%

+78.8%

+41.3%

-25.9%

+5.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-8.13

N/A

5.19

13.38

10.75

-7.51

$226.84M

Profitability

Profit margins and return metrics

Profit Margin -140.8%

Operating Margin -417.78%

Gross Margin 19.19%

ROE -63.86%

ROA -19.77%

Growth

Revenue and earnings growth rates

Revenue Growth -68.0%

Earnings Growth N/A

Q/Q Revenue Growth -68.03%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.2

Low debt

Current Ratio

2.33

Strong

Quick Ratio

2.16

Excellent

Cash/Share

$4.14

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

14.9%

Op. Margin

-418.5%

Net Margin

-384.7%

Total Assets

$0.1B

Liabilities

$0.0B

Equity

$0.0B

Debt/Equity

0.98x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

181%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-20

$N/A

2026-03-05

$-0.56

+8.5% surprise

2025-11-20

$-0.24

+71.0% surprise

2025-08-14

$-1.23

-116.5% surprise

Healthcare Sector Comparison

Comparing MDWD against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)

Return on Equity (ROE)

-63.86%

This Stock

-86.0%

Sector Avg

-25.7% (Below Avg)

Profit Margin

-140.8%

This Stock

-11.76%

Sector Avg

+1097.4% (Superior)

Debt to Equity

0.2

This Stock

3.51

Sector Avg

-94.3% (Less Debt)

Revenue Growth

-68.0%

This Stock

90.15%

Sector Avg

-175.4% (Slower)

Current Ratio

2.33

This Stock

3.67

Sector Avg

-36.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
MDWD MediWound Ltd.	BEARISH	$226.84M	-	-63.9%	-140.8%	$17.65
MGNX MacroGenics, Inc.	BEARISH	$220.55M	-	-86.9%	-49.9%	$3.47	Compare
CVRX CVRx, Inc.	BEARISH	$220.23M	-	-96.6%	-94.1%	$8.37	Compare
LUCD Lucid Diagnostics Inc.	BEARISH	$218.06M	-	-710.6%	-%	$1.28	Compare
CAMP CAMP4 THERAPEUTICS CORPORATION	BEARISH	$241.42M	-	-145.1%	-%	$4.65	Compare

MDWD MediWound Ltd.

BEARISH

Mkt Cap

$227M

P/E

ROE

-63.9%

Price

$17.65

MGNX MacroGenics, Inc.

Compare with MDWD

Compare with MDWD

LUCD Lucid Diagnostics Inc.

Compare with MDWD

Compare with MDWD

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

6 analysts

HC Wainwright & Co.

2025-11-21

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning MDWD from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

MDWD

MDWD MediWound Ltd. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!